← Leaderboards
Richard Saul
Mellitus, Llc
$2,818,192
Attributed
$2,818,192
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2020–21$2M$1.5M$1M$500K$0
'20
'21
Funding mix
By agency
NIH$2,818,192 · 2
By mechanism
R44$2,818,192 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Interest”
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,428,847
- Julie Brisset · The University Of Central Florida Board Of Trustees$41,275,036
- Gary Kobinger · University Of Texas Med Br Galveston$34,500,000
- Lynn Briscoe · Leidos Biomedical Research, Inc.$33,108,860
Research focus
InterestNovel MarkerEpidemicGrantMetabolicDiagnosisDiagnostic TestsEnzyme-Linked Immunosorbent AssayGestational DiabetesGlycationManualsBiologyAssay DevelopmentBloodConsumptionDiabetes MellitusAwardEarly DiagnosisBaseGenerationsAntibodiesDetectionDiagnosticPlasma
Grant awards (3)
Urine glycated CD59 as novel diabetes biomarker amenable to measure with a point-of-care device$1,000,000
R44 · FY2021 · DK · contact PI
Urine glycated CD59 as novel diabetes biomarker amenable to measure with a point-of-care device$1,000,000
R44 · FY2020 · DK · contact PI
An automated test for gestational diabetes based on glycated CD59$818,192
R44 · FY2020 · DK · contact PI